Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gdansk – page 82

1 144 clinical trials in Gdansk, Poland across 11 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gdansk at a glance
1 144
clinical trials
  • Research sites11
Type of trial
Recruitment status
Quick filters

1 144 trials in Gdansk

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of datopotamab deruxtecan combined with immunotherapy and carboplatin in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Effectiveness and Safety of Crovalimab vs. Eculizumab for Adults and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated with Complement Inhibitors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Osteoarthritis

Not recruiting

Effects of Diclofenac Diethylamine Gel on Physical Activity and Quality of Life in Patients with Mild Knee Osteoarthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Diethylamine
  • Sponsor:Haleon CH SARL

Myelofibrosis

Not recruiting

Study on Extended Access to Momelotinib for Patients with Myelofibrosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Small cell lung cancer extensive stage

Not recruiting

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Gdansk

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on bladder cancer, lymphoma, and various advanced solid tumors. Studies are evaluating novel combination therapies and investigating treatments for non-small cell lung cancer.

  • Bladder Cancer Immunotherapy
  • B-Cell Lymphoma Treatment
  • Gastric Cancer Therapeutics

Research includes promising approaches combining established treatments with new immunotherapy agents.

02 Dermatology Studies

Clinical investigations targeting plaque psoriasis, genital psoriasis, and atopic dermatitis. Studies are examining oral and subcutaneous treatments for moderate to severe skin conditions.

  • Psoriasis Management
  • Hidradenitis Suppurativa
  • Novel Dermatological Therapies

Focus on developing targeted treatments for chronic skin conditions affecting quality of life.

03 Metabolic Disorders

Comprehensive research into obesity and weight management, including studies for patients with and without type 2 diabetes. Trials are evaluating new therapeutic approaches for weight reduction.

  • Weight Management Solutions
  • Diabetes Treatment
  • Cardiovascular Risk Management

Investigation of innovative treatments combining lifestyle modifications with pharmaceutical interventions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.